TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02962167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Measles Virus Lumbar Puncture
Description: Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
Study: NCT04179006

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)
Description: 3 pieces per day
Study: NCT03661203

Intervention type: BEHAVIORAL
Intervention: Individual interview
Description: Individual interview for qualitative group only

Intervention type: BEHAVIORAL
Intervention: online self questionnaire
Description: online self questionnaire
Study: NCT04179006

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)
Description: 3 pieces per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)
Description: 3 pieces per day
Study: NCT04524858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450
Description: Oral, small molecule MK2 inhibitor
Study: NCT01204749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Weekly Intravenous (IV) AMG 386 15 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 386 Placebo
Description: Weekly Intravenous (IV) placebo 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
Study: NCT04333368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord Wharton's jelly-derived human
Description: Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5
Study: NCT00549640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
Study: NCT05406011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pelleted sour cherry (anthocyanin) containing chewing gum usage.
Description: Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pelleted sour cherry (anthocyanin) containing chewing gum usage.
Description: Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pelleted sour cherry (anthocyanin) containing chewing gum usage.
Description: Dietary Supplement usage (daily 3 times for 2 weeks) with salivary sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week. Procedure: Scaling after a control period without sour cherry chewing gum usage (1 week).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pelleted chewing gum for stimulated saliva sampling.
Description: Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pelleted chewing gum for stimulated saliva sampling.
Description: Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pelleted chewing gum for stimulated saliva sampling.
Description: Stimulated saliva sampling after chewing a pelleted gum without active ingredient (used only before stimulated saliva sampling), during the whole experimental period (control and parallel with sour cherry chewing gum usage) with sampling on fixed days (1., 4. and 7.) and daytime (between 12:00 and 14:00) of the week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling
Description: Scaling after a 1-week control period without chewing the sour cherry gum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling
Description: Scaling after a 1-week control period without chewing the sour cherry gum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling
Description: Scaling after a 1-week control period without chewing the sour cherry gum.
Study: NCT03980249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
Study: NCT00330759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 milligrams by subcutaneous injection every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: 4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
Study: NCT00006252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBSC
Description: 2-8,000,000/kg CD34+ cells via infusion on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 ug/kg/day subQ injection until ANC \> 1000/uL for 3 days beginning Day 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocytes
Description: 10,000,000 CD3+ cells/kg via infusion
Study: NCT03639363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate soap-like solution
Description: 1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard soap
Description: 1. humidify the whole body surface with the exception of the face using water-impregnated washcloths~2. use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~3. wait for at least 30 seconds~4. rinse using water-impregnated washcloths
Study: NCT00803283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromprphone Hydrochloride (HCl) OROS
Description: Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sustain Release (SR)
Description: Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
Study: NCT03661203

Intervention type: BEHAVIORAL
Intervention: self questionnaire
Description: online self questionnaire following focus group or individual interview For qualitative group only
Study: NCT01999296

Intervention type: DEVICE
Intervention: Use of Thunderbeat (TM) in laparoscopic surgery
Study: NCT01187940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEGASUS
Description: PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
Study: NCT01155336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza®
Description: Lovaza® is prescription grade EPA+DHA fish oil supplement.
Study: NCT02842320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological samples
Description: bone marrow and blood
Study: NCT02437253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
Study: NCT01155336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo contained 1 gram of corn oil in each capsule.
Description: Placebo Pill
Study: NCT05437523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constipation Action Plan
Description: The author team previously developed and assessed this constipation action plan using the universal precautions approach to produce a tool which could optimize knowledge transfer from clinicians to patients, and support stepwise home self-management of functional constipation. The Uniformed Services Constipation Action Plan can be freely downloaded at the following web link: https://wrnmmc.libguides.com/pediatrics/USAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care without constipation action plan
Description: Standard of care without constipation action plan
Study: NCT02072863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Study subjects will receive oprozomib administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Study subjects will receive melphalan 9 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Study subjects will receive prednisone 60 mg/m2.
Study: NCT00548600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iridium Implant
Description: Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard external beam irradiation
Description: Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
Study: NCT02625792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endo-Clot(TM)
Description: After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
Study: NCT02437253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo
Study: NCT01050790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
Study: NCT02904031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT04641845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cork inlay wedge
Study: NCT02366195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: The initial dose of talimogene laherparepvec is up to 4.0 mL of 10\^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10\^8 PFU/mL.
Study: NCT02904031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Study: NCT01599000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination
Description: fixed-dose tablet, six doses over three days, according to weight group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Description: fixed-dose tablet, six doses over three days, according to weight group
Study: NCT02318563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: A matching oral solution containing no cannabidiol
Study: NCT01338818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA (methylphenidate hydrochloride extended release)
Description: Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
Study: NCT02232217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy Sleep
Description: Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
Study: NCT01495208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: intravitreal aflibercept injection 2mg
Study: NCT02510625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomic Glenoid Reconstruction
Description: Distal tibia bone graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic bankart Repair
Description: Arthroscopic bankart Repair
Study: NCT02507388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 3 mg/50 μL
Description: Administered as an intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg/50 μL
Description: Administered as an intravitreal injection
Study: NCT01721161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB033 (anti-LINGO-1 mAb)
Description: 100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
Study: NCT02003326

Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory markers
Study: NCT00360412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Study: NCT02753946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01
Description: 6g ZTI-01 intravenous infusion TID q8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam
Description: 4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
Study: NCT00924027

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Radiation (HDR) Brachytherapy
Description: Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: When deemed necessary.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Obtained based on the sites of target, as clinical situation dictates and at each follow-up to determine local control.
Study: NCT04221724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program
Description: The intervention consists of a combined multicomponent exercise program (EP) carried out for 6 months that includes strength, balance, flexibility and functional exercises aimed to improve functioning on daily life activities. The EP will be divided into two parts:~The first 3 months the EP aims to restore the physical condition through the multicomponent exercise program. This program will comprise of upper and lower body strengthening exercises, using external weights for 2-3sets of 8-12repetitions at a progressive intensity of 30-50% of 1RM. In addition, static balance and flexibility exercise will be performed.~From 3th to 6th months, the objective will be to improve autonomy through the functional EP. Strength exercises intensity will be increased to 60-70% of 1-RM, 2-3sets of 8-12repetitions. Attention tasks, temporal space dissociation and dynamic balance exercises will be added to increase the intensity in balance exercises. Flexibility and fine handle will be also performed
Study: NCT03367728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: TAP and Rectus Sheath Block Injections of Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: TAP and Rectus Sheath Block Injections of Normal Saline
Study: NCT01014130

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HypoRT)
Description: Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Radiotherapy (ConRT)
Description: Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
Study: NCT03626259

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan and Amlodipine
Description: Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
Study: NCT02320916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 23Gauge
Description: Arterial puncture will be made using a 23Gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25Gauge
Description: Arterial puncture will be made using a 25Gauge needle
Study: NCT04001712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: caffeine citrate is given early to preterm neonates in need of respiratory support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate
Description: caffeine citrate is given early to preterm neonates in need of respiratory support
Study: NCT00895284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Description: Robotic hysterectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hysterectomy
Description: Standard hysterectomy.
Study: NCT04694690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self adhesive resin cement
Description: Self adhesive resin cement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin cement
Description: Resin Cement system used after surface treatment
Study: NCT04507243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active - HD tDCS
Description: Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
Study: NCT00924027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: When deemed necessary.
Study: NCT00904046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg orally daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally once a day for 6 months.
Study: NCT05718466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study: NCT04507243

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham - HD tDCS
Description: Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.